B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,329 shares of the biopharmaceutical company’s stock after selling 1,092 shares during the quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Gilead Sciences were worth $671,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its position in shares of Gilead Sciences by 95.7% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock valued at $34,658,000 after purchasing an additional 271,000 shares during the last quarter. Chilton Capital Management LLC grew its position in shares of Gilead Sciences by 3.5% in the fourth quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 555 shares during the last quarter. Nicholas Company Inc. grew its position in shares of Gilead Sciences by 2.7% in the fourth quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after purchasing an additional 13,500 shares during the last quarter. Sectoral Asset Management Inc grew its position in shares of Gilead Sciences by 59.6% in the fourth quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after purchasing an additional 158,750 shares during the last quarter. Finally, AIMZ Investment Advisors LLC boosted its stake in shares of Gilead Sciences by 39.9% in the fourth quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after buying an additional 15,333 shares during the period. 78.78% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ GILD opened at $66.36 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The firm has a market cap of $84.60 billion, a price-to-earnings ratio of 10.79, a price-to-earnings-growth ratio of 0.64 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The firm had revenue of $5.28 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the company earned $1.48 earnings per share. The company’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.80%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s payout ratio is presently 40.98%.
In other Gilead Sciences news, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total transaction of $186,104.52. Following the completion of the sale, the director now directly owns 57,728 shares in the company, valued at $3,745,969.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Insiders have sold 28,602 shares of company stock valued at $1,863,445 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Several brokerages recently issued reports on GILD. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 price target for the company in a research note on Tuesday, April 23rd. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, June 5th. Oppenheimer set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. Maxim Group reiterated a “buy” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Friday, March 29th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $87.00 price target on shares of Gilead Sciences in a research note on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $79.54.
ILLEGAL ACTIVITY NOTICE: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2019/06/17/gilead-sciences-inc-nasdaqgild-holdings-trimmed-by-b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund.html.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: How do candlesticks reflect price movement?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.